RT Journal Article
SR Electronic
T1 Predictors of poor disease control and impaired quality of life (QOL) in patients with severe asthma (SA) in the Wessex Severe Asthma Cohort (WSAC)
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 4228
DO 10.1183/13993003.congress-2022.4228
VO 60
IS suppl 66
A1 V Bataduwaarachchi
A1 T Brown
A1 L Wiffen
A1 T Jones
A1 C Barber
A1 P Howarth
A1 C Anoop
YR 2022
UL http://erj.ersjournals.com/content/60/suppl_66/4228.abstract
AB Introduction: Whilst poor disease control and significant QOL impairment are well recognised in patients with SA the factors associated with these important patient-centred measures are not well established.Methods: WSAC is a large, published cohort of well characterised ‘real-world’ patients fulfilling the ATS/ERS 2014 definition of SA. The association between 39 pre-specified clinical, physiological, and biological ‘predictor’ variables and both asthma control (ACQ6) and asthma related quality of life (AQLQ) were examined in a multivariate analysis using linear regression with backward deletion.Results: In WSAC the median [IQR] ACQ6 score was 2.8 [1.8, 3.7] & AQLQ score was 4 [3.3, 4.9] consistent with poor disease control and impaired QOL. Significant associations within the multivariate model are shown in Fig 1.Conclusion: This analysis has identified several independent ‘predictor’ variables associated with higher ACQ6 (poorer asthma control) & lower AQLQ (poorer QOL) scores including current smoking, obesity and depression which are all well established and important targetable traits in SA. Maintenance OCS use was also independently associated with poorer disease control and QOL potentially reflecting both disease severity but also the side-effects associated with this treatment. Interestingly a significant blood eosinophilia was independently associated with a higher ACQ6 score potentially suggesting a relationship between T2 inflammation & disease burden in SA. WSAC reflects a real-world severe asthma population and an improved focus of targetable traits will facilitate the development of personalised care for these patients.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 4228.This article was presented at the 2022 ERS International Congress, in session “-”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).